Mirati’s New CEO Clears Out Execs Ahead Of Key Filing And Readout
Keytruda Combo Data Next Week
The biotech could have the best-in-class KRAS inhibitor, but the departure of two senior executives has given investors the jitters as Mirati heads towards its first regulatory filing.
